Rigel Pharma upgraded by Jefferies with a new price target
$RIGL
Biotechnology: Pharmaceutical Preparations
Health Care
Jefferies upgraded Rigel Pharma from Hold to Buy and set a new price target of $42.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2025 | $42.00 | Hold → Buy | Jefferies |
| 4/3/2023 | $2.00 | Neutral | Piper Sandler |
| 6/9/2022 | Buy → Neutral | Citigroup | |
| 6/8/2022 | $7.00 → $1.00 | Overweight → Neutral | Piper Sandler |
| 6/8/2022 | $6.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
| 3/23/2022 | $4.00 | Neutral | B. Riley Securities |
SOUTH SAN FRANCISCO, Calif., May 27, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:45 a.m. ET in New York, NY.To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a biotechn
Oral presentation at ASCO Annual Meeting to feature final data from the Phase 3 AcceleRET-Lung clinical trial of GAVRETO® (pralsetinib) as first-line treatment in patients with RET fusion-positive NSCLCFinal analysis from the Phase 1/2 ARROW clinical trial of pralsetinib in patients with advanced or metastatic RET-altered thyroid cancer to be presented in a poster sessionReal-world data further supports the use of REZLIDHIA® (olutasidenib) in patients with R/R mIDH1 AML that have received prior venetoclaxSOUTH SAN FRANCISCO, Calif., May 21, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, tod
SOUTH SAN FRANCISCO, Calif., May 14, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the 2026 RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, at 9:30 a.m. ET in New York, NY.To access the live webcast or archived recording, visit the Investor Relations section of the company's website at www.rigel.com. Please connect to Rigel's website prior to the start of the live webcast to allow for any software downloads.About RigelRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is
Jefferies upgraded Rigel Pharma from Hold to Buy and set a new price target of $42.00
Piper Sandler resumed coverage of Rigel Pharma with a rating of Neutral and set a new price target of $2.00
Citigroup downgraded Rigel Pharma from Buy to Neutral
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
4 - RIGEL PHARMACEUTICALS INC (0001034842) (Issuer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
8-K - RIGEL PHARMACEUTICALS INC (0001034842) (Filer)
SOUTH SAN FRANCISCO, Calif., Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries. "Mike has a strong track record of commercial excellence, and we're delighted to have him join our Board," said Raul Rodriguez, Rigel's president and CEO. "His extensive expertise in commercial execution and leadership will provide valuable insights as we execute on our transformational strategic plan, particularly our objectives of growing our current portfolio of medicines
SOUTH SAN FRANCISCO, Calif., March 10, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 years of experience developing cellular immunotherapies to treat cancer, including deep expertise in clinical drug development and translational research, and portfolio strategy. "We are pleased to have Mark join our Board," said Raul Rodriguez, Rigel's president and CEO. "His experience in clinical development, translational research and portfolio strategy will be a valuable addition to Rigel as we advance our hematology and oncology developm
SOUTH SAN FRANCISCO, Calif., March 12, 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background. "It is a pleasure to welcome Lisa to the team. She brings to Rigel a strong combination of industry leadership experience paired with drug development and regulatory affairs expertise. Her robust hematology and oncology knowledge comp
VEPPANU has a novel mechanism of action, is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HER2-, ESR1-mutated mBCPivotal Phase 3 VERITAC-2 clinical trial results showed that vepdegestrant was generally well tolerated and reported mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement, in patients with 2L+ ER+/HER2- mBC with an ESR1 mutationUpon closing of the transaction, VEPPANU will become Rigel's fourth commercial product and its major focus to accelerate revenue growth while leveraging the company's existing infrastructure, contributing meaningfully to the advancement of Rigel's
First quarter 2026 total revenues of $58.8 million, including net product sales of $54.9 million and contract revenues from collaborations of $3.9 millionGenerated $8.7 million of net income in the first quarter of 2026On track to complete enrollment in the dose expansion phase of the Phase 1b study evaluating R289 and select the recommended Phase 2 dose in the second half of 20262026 Outlook: Total revenues of approximately $275 to $290 million, which includes net product sales of $255 to $265 millionConference call and webcast scheduled today at 4:30 p.m. Eastern TimeSOUTH SAN FRANCISCO, Calif., May 5, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), a commercial stage biote
SOUTH SAN FRANCISCO, Calif., April 28, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) today announced that it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results and give an update on the business.Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's websi
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G/A - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)
SC 13G - RIGEL PHARMACEUTICALS INC (0001034842) (Subject)